6 results about "Pancreas Inflammation" patented technology

The invention discloses a preparation method and application of a szechwan chinaberry fruit powder extract, and relates to the technical field of Chinese herbal medicines. The method comprises the following steps: respectively crushing and sieving fructus toosendan and rhizoma corydalis decoction pieces, mixing, adding low-concentration ethanol into the mixed powder, and stirring and extracting; sequentially filtering and centrifuging the extracting solution, and collecting supernate; and concentrating the supernate, and performing freeze-drying treatment to obtain the szechwan chinaberry fruit powder extract. Researches find that the extract can significantly reduce amylase and lipase levels in an acute pancreatitis cell model; the general state of a mouse with severe acute pancreatitis is obviously improved, the serum amylase and lipase levels are reduced, the pathological injury of pancreas is relieved, the inflammatory response is inhibited, the infiltration of pancreatic macrophages is inhibited, and the lung injury caused by pancreatitis is effectively improved.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

The invention discloses application of butylphthalide in preparation of a medicine for preventing and treating obesity-related acute pancreatitis, and belongs to the technical field of medicines. The invention discloses application of butylphthalide in treatment of obesity-related acute pancreatitis. Pancreatic necrosis, systemic inflammation and distant organ injury caused by obesity-related acute pancreatitis can be remarkably improved. Wherein after intervention of butylphthalide, pathological scores of lung, kidney and pancreas are obviously reduced by 73.08%, 70.00% and 59.26%; the expression level of the pancreatitis marker is obviously reduced and is reduced by 53.80% compared with that of a model group; the expression levels of proinflammatory factors IL-1beta, IL-6 and TNF-alpha in serum are obviously reduced, and are respectively reduced by 69.45%, 78.80% and 67.64% compared with a model group.

The application relates to the field of biological medicine, and particularly relates to application of xanthine nucleoside in preparation of a drug for preventing and treating acute pancreatitis. In the application, it is found that the xanthine nucleoside can significantly improve pancreas inflammation, necrosis and systemic inflammatory response caused by acute pancreatitis, the xanthine nucleoside is used in preparation of the drug for preventing and treating acute pancreatitis, a new strategy is provided for preventing and treating acute pancreatitis, and the application has a good clinical application prospect.

The application belongs to the technical field of medicine preparation, and particularly relates to a curcumin-loaded cerium-based nanoenzyme as well as a preparation method and application thereof. The curcumin-loaded cerium-based nanoenzyme comprises a core carrier, a drug loaded on the core carrier and a shell; the core carrier is a cerium metal organic framework; the drug is curcumin; and the shell is hyaluronic acid. The application provides a super-small nanoenzyme HC@CeMOF with strong antioxidant and targeting functions, and data results of the application show that the HC@CeMOF can be used for treating chronic pancreatitis. Specifically, the HC@CeMOF can be used for treating chronic pancreatitis by utilizing the inflammation targeting ability of hyaluronic acid, so that the HC@CeMOF is preferentially gathered at a chronic pancreatitis inflammation site, then through the synergistic effect of curcumin and CeMOF, active oxygen (ROS) at the lesion site is effectively removed, and the expression of NF-kappa B is down-regulated, so as to regulate the local inflammatory cytokine microenvironment, and finally significantly improve the pancreas fibrosis.

The invention relates to a fusion protein containing selenomethionine and application of the fusion protein in treating acute pancreatitis, and belongs to the technical field of biological medicines. The fusion protein is prepared from a TAT-14-PTD-p65 fusion protein and organic selenium (selected from selenomethionine) through an in-vivo biochelation method, the fusion protein adopts an Nrf2 activation-NF-kappa B inhibition-selenium donor three-in-one design, and comprises an Nrf2 activation element (TAT-14 peptide), an NF-kappa B inhibition element (PTD-p65-P1) and a selenium donor element (selenomethionine) which are connected through a (Gly4Ser) 2 connecting peptide so as to avoid spatial interference. Experiments show that the fusion protein and the selenium chelate thereof can significantly reduce serum lipase and amylase levels of C57 mice with acute pancreatitis, inhibit inflammatory response and oxidative stress and relieve pancreatic tissue damage by inhibiting pancreatic tissue NF-kB inflammatory pathway activation and up-regulating pancreatic Nrf2 / HO-1 antioxidant pathway, and the selenium chelate has a better effect.